Kaken Pharmaceutical Co Ltd
TSE:4521
Intrinsic Value
Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. [ Read More ]
The intrinsic value of one Kaken Pharmaceutical Co Ltd stock under the Base Case scenario is 2 606.68 JPY. Compared to the current market price of 3 389 JPY, Kaken Pharmaceutical Co Ltd is Overvalued by 23%.
Valuation Backtest
Kaken Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling Kaken Pharmaceutical Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Kaken Pharmaceutical Co Ltd
| Current Assets | 110.3B |
| Cash & Short-Term Investments | 66.2B |
| Receivables | 24.6B |
| Other Current Assets | 19.6B |
| Non-Current Assets | 58B |
| Long-Term Investments | 19.5B |
| PP&E | 24.5B |
| Intangibles | 7.5B |
| Other Non-Current Assets | 6.5B |
| Current Liabilities | 19.6B |
| Accounts Payable | 8.3B |
| Accrued Liabilities | 461m |
| Short-Term Debt | 3.9B |
| Other Current Liabilities | 7B |
| Non-Current Liabilities | 8.7B |
| Other Non-Current Liabilities | 8.7B |
Earnings Waterfall
Kaken Pharmaceutical Co Ltd
|
Revenue
|
72.1B
JPY
|
|
Cost of Revenue
|
-33.2B
JPY
|
|
Gross Profit
|
38.9B
JPY
|
|
Operating Expenses
|
-34.4B
JPY
|
|
Operating Income
|
4.5B
JPY
|
|
Other Expenses
|
-1.5B
JPY
|
|
Net Income
|
3B
JPY
|
Free Cash Flow Analysis
Kaken Pharmaceutical Co Ltd
Profitability Score
Profitability Due Diligence
Kaken Pharmaceutical Co Ltd's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Kaken Pharmaceutical Co Ltd's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Kaken Pharmaceutical Co Ltd's solvency score is 97/100. The higher the solvency score, the more solvent the company is.
Score
Kaken Pharmaceutical Co Ltd's solvency score is 97/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Kaken Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for Kaken Pharmaceutical Co Ltd is 3 570 JPY with a low forecast of 3 535 JPY and a high forecast of 3 675 JPY.
Shareholder Return
Price
Kaken Pharmaceutical Co Ltd
| Average Annual Return | -0.51% |
| Standard Deviation of Annual Returns | 24.1% |
| Max Drawdown | -42% |
| Market Capitalization | 128.3B JPY |
| Shares Outstanding | 37 869 858 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. The company is headquartered in Bunkyo-Ku, Tokyo-To and currently employs 1,215 full-time employees. The firm operates in two business segments. The Pharmaceutical segment involves in the manufacture and sale of pharmaceuticals, medical devices and agricultural drugs. The Real Estate segment is engaged in the leasing of real estate.
Contact
IPO
Employees
Officers
The intrinsic value of one Kaken Pharmaceutical Co Ltd stock under the Base Case scenario is 2 606.68 JPY.
Compared to the current market price of 3 389 JPY, Kaken Pharmaceutical Co Ltd is Overvalued by 23%.
You don't have any saved screeners yet
